These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17328229)

  • 1. The promise of CCR5 antagonists as new therapies for HIV-1.
    Repik A; Richards KH; Clapham PR
    Curr Opin Investig Drugs; 2007 Feb; 8(2):130-9. PubMed ID: 17328229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV co-receptors as targets for antiviral therapy.
    Schols D
    Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs.
    Seibert C; Sakmar TP
    Curr Pharm Des; 2004; 10(17):2041-62. PubMed ID: 15279544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
    De Clercq E; Schols D
    Antivir Chem Chemother; 2001; 12 Suppl 1():19-31. PubMed ID: 11594685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-receptor antagonists as HIV-1 entry inhibitors.
    Shaheen F; Collman RG
    Curr Opin Infect Dis; 2004 Feb; 17(1):7-16. PubMed ID: 15090884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
    Princen K; Schols D
    Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemokine receptor-directed agents as novel anti-HIV-1 therapies.
    Mills SG; DeMartino JA
    Curr Top Med Chem; 2004; 4(10):1017-33. PubMed ID: 15193136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection.
    Westby M; van der Ryst E
    Antivir Chem Chemother; 2005; 16(6):339-54. PubMed ID: 16329283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral CCR5 inhibitors: will they make it through?
    Biswas P; Nozza S; Scarlatti G; Lazzarin A; Tambussi G
    Expert Opin Investig Drugs; 2006 May; 15(5):451-64. PubMed ID: 16634684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel inhibitors of the early steps of the HIV-1 life cycle.
    Citterio P; Rusconi S
    Expert Opin Investig Drugs; 2007 Jan; 16(1):11-23. PubMed ID: 17155850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy.
    Grande F; Occhiuzzi MA; Rizzuti B; Ioele G; De Luca M; Tucci P; Svicher V; Aquaro S; Garofalo A
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30717348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Gymnastics: Mechanisms of HIV-1 Resistance to CCR5 Antagonists and Impact on Virus Phenotypes.
    Roche M; Borm K; Flynn JK; Lewin SR; Churchill MJ; Gorry PR
    Curr Top Med Chem; 2016; 16(10):1091-106. PubMed ID: 26324043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.
    Bredeek UF; Harbour MJ
    Eur J Med Res; 2007 Oct; 12(9):427-34. PubMed ID: 17933724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting chemokine receptors for HIV: past, present and future.
    Fricker SP
    Future Med Chem; 2015; 7(17):2311-5. PubMed ID: 26627446
    [No Abstract]   [Full Text] [Related]  

  • 15. The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies.
    Dhami H; Fritz CE; Gankin B; Pak SH; Yi W; Seya MJ; Raffa RB; Nagar S
    J Clin Pharm Ther; 2009 Apr; 34(2):147-60. PubMed ID: 19250135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
    Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
    J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV/AIDS: recent advances in antiretroviral agents.
    Nikolopoulos G; Bonovas S; Tsantes A; Sitaras NM
    Mini Rev Med Chem; 2009 Jul; 9(8):900-10. PubMed ID: 19601885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy.
    Mohamed H; Gurrola T; Berman R; Collins M; Sariyer IK; Nonnemacher MR; Wigdahl B
    Front Immunol; 2021; 12():816515. PubMed ID: 35126374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New agents for the inhibition of HIV replication.
    Miles S
    HIV Clin Trials; 2000; 1(2):29-30. PubMed ID: 11590496
    [No Abstract]   [Full Text] [Related]  

  • 20. CCR5 antagonists: a new tool in fighting HIV.
    Jülg B; Goebel FD
    J HIV Ther; 2005 Dec; 10(4):68-71. PubMed ID: 16519245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.